Gastroenterology
Volume 96, Issue 2, Part 1 , Pages 442-448 , February 1989

Inhibition of antibody secretion by 5-aminosalicylic acid

Received 7 January 1988 ,Accepted 26 September 1988.

References 

  1. Brandtzaeg P, Baklien K, Fausa O, Hoel PS. Immunohistochemical characterization of local immunoglobulin formation in ulcerative colitis. Gastroenterology. 1974;66:1123–1136
  2. Baklien K, Brandtzaeg P. Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon. Clin Exp Immunol. 1975;22:197–209
  3. Rosekrans PCM, Meijer CJLM, Van der Wal AM, Cornelisse CJ, Lindeman J. Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut. 1980;21:941–947
  4. Scott BB, Goodall A, Stephenson P, Jenkins D. Rectal mucosal plasma cells in inflammatory bowel disease. Gut. 1983;24:519–524
  5. Keren DF, Appelman HD, Dobbins WO, et al.  Correlation of histopathologic evidence of disease activity with the presence of immunoglobulin-containing cells in the colons of patients with inflammatory bowel disease. Hum Pathol. 1984;15:757–763
  6. MacDermott RP, Nash GS, Bertovich MJ, Seiden MV, Bragdon MJ, Beale MG. Alterations of IgM, IgG, and IgA synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease. Gastroenterology. 1981;81:844–852
  7. MacDermott RP, Beale MG, Alley CD, Nash GS, Bertovich MJ, Bragdon MJ. Synthesis and secretion of IgA, IgM, and IgG by peripheral blood mononuclear cells in human disease states, by isolated human intestinal mononuclear cells, and by human bone marrow mononuclear cells from ribs. In: The secretory immune system. 2nd ed.  McGhee JR,  Mestecky J editor. Annals of the New York Academy of Sciences. Volume 409:New York: New York Academy of Sciences; 1983;p. 498–509
  8. MacDermott RP, Nash GS, Bertovich MJ, et al.  Altered patterns of secretion of monomeric IgA and IgA subclass 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology. 1986;91:379–385
  9. Scott MG, Nahm MH, Macke K, Nash GS, Bertovich MJ, MacDermott RP. Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol. 1986;66:209–215
  10. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980;303:1499–1502
  11. Hawkey CJ, Truelove SC. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut. 1983;24:213–217
  12. Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982;69:494–497
  13. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulfasalazine and its metabolites on the generation of reactive oxygen species. Gut. 1987;28:190–195
  14. Boyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21:31–50
  15. MacDermott RP, Franklin GO, Jenkins KM, Kodner KJ, Nash GS, Weinrieb IJ. Human intestinal mononuclear cells: I. Investigation of antibody-dependent, lectin-induced, and spontaneous cell-mediated cytotoxic capabilities. Gastroenterology. 1980;78:47–56
  16. MacDermott RP, Bragdon MJ, Jenkins KM, Franklin GO, Shedlofsky S, Kodner KJ. Human intestinal mononuclear cells: II. Demonstration of a naturally occurring subclass of T cells which respond in the allogeneic mixed leukocyte reaction but do not effect cell-mediated lympholysis. Gastroenterology. 1981;80:748–757
  17. Bookman MA, Bull DM. Characteristics of isolated intestinal mucosal lymphoid cells in inflammatory bowel disease. Gastroenterology. 1979;77:503–510
  18. Nash GS, Seiden MV, Beale MG, MacDermott RP. A rapid miniaturized solid-phase radioimmunoassay technique for secreted immunoglobulins, employing microtiter plates, antibody bound to polyacrylamide beads, and filter strip harvesting. J Immunol Methods. 1982;49:261–269
  19. MacDermott RP, Stenson WF. Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol. 1988;42:285–328
  20. Thayer WR, Charland C, Field CE. Effects of Sulfasalazine on selected lymphocyte subpopulations in vivo and in vitro. Dig Dis Sci. 1979;24:672–679
  21. Rubinstein A, Das KM, Melamed J, Murphy RA. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of Sulfasalazine in vivo and in vitro. Clin Exp Immunol. 1978;33:217–224
  22. Holdstock G, Chastenay BF, Krawitt EL. Increased suppressor cell activity in inflammatory bowel disease. Gut. 1981;22:1025–1030
  23. MacDermott RP, Kane MG, Steele LL, Stenson WF. Inhibition of cytotoxicity by Sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from control and inflammatory bowel disease patients. Immunopharmacology. 1986;11:101–109
  24. Shanahan F, Niederlehner A, MacDermott RP, Stenson WF, Kane MG, Targan S. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology. 1986;11:111–118
  25. MacDermott RP, Nahm MH. Expression of human immunoglobulin G subclasses in inflammatory bowel disease. Gastroenterology. 1987;93:1127–1134
  26. Stenson WF, Parker CW. Prostaglandins. In:  Sirois P,  Rola Pleszczynski M editor. Immunopharmacology. Amsterdam: Elsevier; 1982;p. 75–112

☆ This work was supported in part by U.S. Public Health grants DK21474, DK33487, and DK33165; and by grants from the National Foundation for Ileitis and Colitis and from Marion Laboratories.This work was presented at the 89th annual meeting of the American Gastroenterological Association, May 18, 1988, and was published in abstract form (Gastroenterology 1988;94:A275).

PII: 0016-5085(89)91569-2

Gastroenterology
Volume 96, Issue 2, Part 1 , Pages 442-448 , February 1989

Article Tools